NIDDK Announcement: Resources and Funding Available for Research in Nonmalignant Hematology
Dr. Terry Bishop presents a consortium of Cooperative Centers of Excellence in Hematology supported by the Division of Kidney, Urologic, and Hematologic Diseases of the Nat
And Then There Were 10: Dendritic Cells and Monocytes Undergo a Reclassification
Dr. Moss covers a radical revision of the classification of dendritic cells and monocytes.
Dr. Anderson outlines six major ASH strategic initiatives and goals for the coming years discussed at the 2017 Executive Committee Spring Retreat in Canada.
Dr. Roberts looks at a study that compares chemoimmunotherapy with three combinations of non-DNA damaging drugs as first-line therapy for fit patients.
Drs. Rosmarin and Alvarnas update ASH members on key policy topics affecting hematologists, including research funding, drug access and pricing issues, and efforts to repeal the ACA.
July/August 2017 Volume 14, Issue 4
View all Features articles
View all Diffusion articles
Dr. Kenneth Anderson outlines six major ASH strategic initiatives and goals for the coming years discussed at the 2017 Execxutive Committee Spring Retreat in Canada.
View all president's column articles
View all Ask the Hematologist articles
View all Op-Ed articles
View all Mini Review articles
Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations.
On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model. CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.
ASH is pleased to see the National Heart, Lung and Blood Institute’s (NHLBI) continuous support (RFA-HL-15-030) for the development of improved techniques to enhance the production of clinically relevant, functional stem cell-derived red blood cells or platelets.
The American Society of Hematology (ASH) is committed to addressing the burden of sickle cell disease (SCD) and is undertaking a multifaceted initiative to improve outcomes for individuals with
the disease, both in the United States and globally.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology